At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
MSK researchers are studying a new CAR T cell therapy to treat acute myeloid leukemia (AML). They want to evaluate its safety and find the best dose of the new treatment. The adults and children in this study have AML that keeps growing even after treatment. The new CAR T cell therapy is called CD371-CAR-IL18.
- A Phase 3 Study Comparing Ruxolitinib/Tacrolimus/Methotrexate with Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil to Prevent Graft-Versus-Host Disease After a Stem Cell Transplant
Full Title A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203/INCB 18424-370)
Purpose
After a stem cell transplant, some patients develop a condition called graft-versus-host disease (GVHD). This occurs when the donor’s healthy immune cells see the recipient’s normal cells as foreign and attack them.
In this study, researchers want to see if giving ruxolitinib with tacrolimus and methotrexate before and after a stem cell transplant will prevent GVHD. Ruxolitinib is already used to treat GVHD. The people in this study are getting a stem cell transplant as treatment for blood cancer.
The researchers will compare this new approach to the standard treatment, which includes cyclophosphamide, tacrolimus, and mycophenolate mofetil after transplant. If you take part in this study, you will be randomly assigned to get one of these treatments:
- Ruxolitinib with tacrolimus and methotrexate before and after transplant
- Cyclophosphamide, tacrolimus, and mycophenolate mofetil after transplant
Who Can Join
To join this study, there are a few conditions. You must:
- Leukemia, Hodgkin lymphoma, or non-Hodgkin lymphoma that will be treated with a stem cell transplant.
- Have a suitable stem cell donor.
- Be able to walk and do routine activities for more than half the time you are awake.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Miguel-Angel Perales’ office at 646-608-3757.
Protocol
25-075Phase
Phase III (phase 3)Disease Status
Newly Diagnosed & Relapsed/RefractoryInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT06615050ClinicalTrials.gov
-
The purpose of this study is to compare two different approaches to surgery for children and adults with osteosarcoma (bone cancer) that has spread (metastasized) to the lungs. Participants will be randomly assigned to one of two techniques:
-
Researchers want to see if adding cabozantinib to standard chemotherapy works better than chemotherapy alone for osteosarcoma. The people in this study include children, adolescents, and young adults with osteosarcoma that has not yet been treated.
- A Phase 1-2 Study of ECI830 in People With Advanced Breast Cancer and Other Solid Tumors
Full Title An Open-Label, Multi-center, Phase I/II Study of ECI830 as a Single Agent and in Combination with Ribociclib and Endocrine Therapy in Patients with Advanced Hormone Receptor Positive, HER2-Negative Breast Cancer and Advanced Solid Tumors
Purpose
Researchers want to find the highest dose of ECI830 that can be given safely in people with advanced cancer. The people in this study have breast cancer or other solid tumors that have spread beyond their original location.
ECI830 targets and blocks the CDK2 protein. This protein is found on cancer cells and plays a role in cancer growth and survival. By blocking CDK2, ECI830 may help slow or stop the growth of your cancer. It is taken orally (by mouth).
Who Can Join
To join this study, there are a few conditions. You must:
- Have breast cancer or another solid tumor that has spread beyond its original location.
- Have cancer that keeps growing after treatment or cannot be successfully treated with standard therapies.
- Not have had prior treatment with a CDK2 inhibitor.
- Have completed prior therapies at least 4 weeks before taking ECI830.
- Be able to walk and do routine activities for more than half the time you are awake.
- Be age 18 or older.
Contact
For more information and to see if you can join this study, please call Dr. Komal Jhaveri’s office at 646-888-5145.
Protocol
25-178Phase
Phase I/II (phases 1 and 2 combined)Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT06726148ClinicalTrials.gov
-
Researchers want to find the best doses of ziftomenib to use with other drugs to treat leukemia. The people in this study have acute myeloid leukemia (AML) that keeps growing even with treatment. In addition, they have AML with changes in the NPM1, KMT2A, or FLT3 genes.
-
Researchers in this study are assessing a combination of imaging and blood tests to find pancreatic cancer early. The people in this study have an increased risk of this cancer due to pancreatic cysts. They are planning to have surgery to remove the cysts and check them for cancer. It is hoped that the imaging and blood tests can detect pancreatic cancer early so people can avoid surgery.
- A Phase 3 Study Comparing Proton Craniospinal Radiation Therapy With the Usual Radiation Therapy for Leptomeningeal Metastasis
Full Title A Phase III Randomized Clinical Trial of Proton Craniospinal Irradiation Versus Involved-Field Radiotherapy for Patients with Breast Cancer or Non-Small Cell Lung Cancer Leptomeningeal Metastasis (Radiate-LM) (NRG-BN014) (CIRB)
Purpose
Breast cancer and non-small cell lung cancer (NSCLC) can spread to the cerebrospinal fluid-filled space around the brain and spinal cord. This is called leptomeningeal metastasis (LM). The effects of LM on the nervous system can be very serious.
The current standard strategy employs x-rays to treat the brain and specific areas of the spine to relieve or prevent symptoms. This is called involved-field radiation therapy (IFRT).
In this study, researchers are comparing usual IFRT with proton craniospinal irradiation (pCSI). pCSI uses proton radiation to comprehensively treat the entire central nervous system space. This includes the cerebrospinal fluid, brain, and spinal cord.
This study is determining whether pCSI is better than IFRT to treat LM in people with breast cancer or NSCLC. If you take part in this study, you will be randomly assigned to get IFRT or pCSI.
Who Can Join
To join this study, there are a few conditions. You must:
- Have newly diagnosed LM from breast cancer or NSCLC.
- Be able to walk and do routine activities for more than half the time you are awake.
- Be age 18 or older.
Contact
For more information about this study, please call Dr. Yao Yu’s office at 908-542-3427.
Protocol
25-150Phase
Phase III (phase 3)Investigator
Co-Investigators
Locations
ClinicalTrials.gov ID
NCT06500481ClinicalTrials.gov
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.